Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 10, 1997

View Archived Issues

Company Profile: Kos Pharmaceuticals

Cerebrus uses studies on Redux to design new antiobesity agents

International Murex: Q3 1997 highlights

Confirmatory trials of Alpha-Beta's Betafectin to begin

New agents in development for restenosis

Ganaxolone shows promise in phase II epilepsy and migraine trials

Nycomed Amersham merger now completed

Spotlight on thrombin inhibitors

Fibrinogen antagonists from Merck & Co.

Takeda describes new melatonin agonists

Quinoxalinediones for neurodegenerative/neurological disorders patented

Inhibitors of ECE prepared at Roussel Uclaf/INSERM

Novartis reports protein tyrosine kinase inhibitors for bone disorders

New taxoids from RPR

Preclinical and clinical profile of Searle's fibrinogen antagonist

TP-9201 covered by new U.S. patent

Lamifiban efficacy demonstrated in PARAGON trial

NCI supports R&D on antiangiogenic agents at Telios

Fast-track development of calanolide A as anti-AIDS drug

Prionics develops antibody useful for diagnosing and possibly treating prion diseases

RenaGel with and without calcium effective in ESRD

Efficacy of NC-100100 demonstrated in dogs

SB-234551 prevents radiocontrast-induced renal vasoconstriction in dogs

FDA clears Fortovase

Mechanism of action of triptolide investigated in human T-cells

Fibrinogen receptor occupancy, antiplatelet activity and safety of lefradafiban

LXR to commence pivotal trials with HK-Cardiosol

Phase Ia study with NGD-91-2 completed

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 26, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...